The Trophos pipeline is focused on neurology and cardiovascular indications.
Trophos’ olesoxime (TRO19622) clinical development is targeted towards spinal muscular atrophy (SMA) and Multiple Sclerosis (MS).
Olesoxime has also shown promising results obtained in models of Huntington's disease and Alzheimer's disease in the EU funded MitoTarget 3 year project, completed by a pan-European consortium of neurological experts led by Trophos.
Trophos’ TRO40303 is being developed for the indication Cardiac Ischemia-Reperfusion Injury (IRI). TRO40303 is currently the subject of a clinical trial within the MitoCare project run by a pan-European consortium of cardiovascular experts led by Trophos.
Trophos Pipeline Chart: